# Pharmacokinetics and Safety of ALA in Acne Vulgaris

> **NCT04044898** · PHASE1 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** ALA 5%
- **DRUG:** ALA 10%

## Key facts

- **NCT ID:** NCT04044898
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-12-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044898, "Pharmacokinetics and Safety of ALA in Acne Vulgaris". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04044898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*